-
Je něco špatně v tomto záznamu ?
Global Real-World Outcomes of Patients Receiving Immuno-Oncology Combinations for Advanced Renal Cell Carcinoma: The ARON-1 Study
M. Santoni, F. Massari, ZW. Myint, R. Iacovelli, M. Pichler, U. Basso, J. Kopecky, J. Kucharz, S. Buti, M. Rizzo, L. Galli, T. Büttner, U. De Giorgi, R. Kanesvaran, O. Fiala, E. Grande, PA. Zucali, G. Fornarini, MT. Bourlon, S. Scagliarini, J....
Jazyk angličtina Země Francie
Typ dokumentu časopisecké články
NLK
ProQuest Central
od 2006-01-01 do Před 1 rokem
Medline Complete (EBSCOhost)
od 2006-01-01 do Před 1 rokem
Nursing & Allied Health Database (ProQuest)
od 2006-01-01 do Před 1 rokem
Health & Medicine (ProQuest)
od 2006-01-01 do Před 1 rokem
Family Health Database (ProQuest)
od 2006-01-01 do Před 1 rokem
- MeSH
- doba přežití bez progrese choroby MeSH
- inhibitory proteinkinas terapeutické užití MeSH
- karcinom z renálních buněk * patologie MeSH
- lidé MeSH
- nádory ledvin * patologie MeSH
- retrospektivní studie MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
BACKGROUND: Immuno-oncology combinations have achieved survival benefits in patients with metastatic renal cell carcinoma (mRCC). OBJECTIVE: The ARON-1 study (NCT05287464) was designed to globally collect real-world data on the use of immuno-combinations as first-line therapy for mRCC patients. PATIENTS AND METHODS: Patients aged ≥ 18 years with a cytologically and/or histologically confirmed diagnosis of mRCC treated with first-line immuno-combination therapies were retrospectively included from 47 International Institutions from 16 countries. Patients were assessed for overall survival (OS), progression-free survival (PFS), and overall clinical benefit (OCB). RESULTS: A total of 729 patients were included; tumor histology was clear-cell RCC in 86% of cases; 313 patients received dual immuno-oncology (IO + IO) therapy while 416 were treated with IO-tyrosine kinase inhibitor (IO + TKI) combinations. In the overall study population, the median OS and PFS were 36.5 and 15.0 months, respectively. The median OS was longer with IO+TKI compared with IO+IO therapy in the 616 patients with intermediate/poor International mRCC Database Consortium (IMDC) risk criteria (55.7 vs 29.7 months; p = 0.045). OCB was 84% for IO+TKI and 72% for IO + IO combination (p < 0.001). CONCLUSIONS: Our study may suggest that immuno-oncology combinations are effective as first-line therapy in the mRCC real-world context, showing outcome differences between IO + IO and IO + TKI combinations in mRCC subpopulations. CLINICAL TRIAL REGISTRATION: NCT05287464.
Chair of Oncology Interdisciplinary Department of Medicine University of Bari Aldo Moro Bari Italy
Department of Biomedical Sciences Humanitas University Pieve Emanuele Milan Italy
Department of Internal Medicine and Medical Specialties University of Genoa Genoa Italy
Department of Internal Medicine Hematology Oncology Ochsner Medical Center New Orleans LA USA
Department of Medical Oncology Army Hospital Research and Referral New Delhi India
Department of Medical Oncology Centre Hospitalier de Jolimont Haine Saint Paul Belgium
Department of Medical Oncology Hospital Ramón y Cajal Madrid Spain
Department of Medical Oncology Maggiore della Carità University Hospital 28100 Novara Italy
Department of Medical Oncology MD Anderson Cancer Center Madrid Madrid Spain
Department of Oncology IRCCS Humanitas Research Hospital Rozzano Milan Italy
Department of Oncology San Camillo Forlanini Hospital Rome Italy
Department of Urology Medical University of Innsbruck Anichstrasse 35 6020 Innsbruck Austria
Department of Urology University Hospital Bonn 53127 Bonn Germany
Dipartimento di Oncologia Medica Fondazione IRCCS Istituto Nazionale dei Tumori Milan Italy
Division of Medical Oncology National Cancer Centre Singapore Singapore Singapore
IRCCS Ospedale Policlinico San Martino Genoa Italy
Latin American Cooperative Oncology Group LACOG Porto Alegre Brazil
Markey Cancer Center University of Kentucky Lexington KY 40536 0293 USA
Medical Oncology 1 IRCCS Regina Elena National Cancer Institute Rome Italy
Medical Oncology Department La Paz University Hospital Madrid Spain
Medical Oncology IRCCS Azienda Ospedaliero Universitaria di Bologna Via Albertoni 15 Bologna Italy
Medical Oncology Ospedale San Paolo 17100 Savona Italy
Medical Oncology Tawam Hospital Al Ain United Arab Emirates
Medical Oncology Unit Santa Chiara Hospital Trento Italy
Oncologia Medica Fondazione Policlinico Universitario Agostino Gemelli IRCCS Rome Italy
Oncologia Medica Ospedale Maggiore di Cremona Cremona Italy
Oncology 3 Unit Department of Oncology Istituto Oncologico Veneto IOV IRCCS Padua Italy
Oncology and Hematology Department Hospital Santa Lucia SHLS 716 Cj C Brasília DF 70390 700 Brazil
Oncology Candiolo Cancer Institute IRCCS FPO 10060 Turin Italy
Oncology Unit 2 University Hospital of Pisa 56126 Pisa Italy
Oncology Unit A R N A S Civico Palermo Italy
Oncology Unit Macerata Hospital Via Santa Lucia 2 62100 Macerata Italy
Unità di Oncologia Medica Azienda Ospedaliero Universitaria di Cagliari Cagliari Italy
UOC di Oncologia Azienda Ospedaliera di Rilievo Nazionale Cardarelli di Napoli Naples Italy
UOC Oncologia Azienda Ospedaliera Ospedali Riuniti Marche Nord Tuscany Italy
Urologic Oncology Champalimaud Clinical Center 1400 038 Lisbon Portugal
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc23016959
- 003
- CZ-PrNML
- 005
- 20231026105438.0
- 007
- ta
- 008
- 231013s2023 fr f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/s11523-023-00978-2 $2 doi
- 035 __
- $a (PubMed)37369815
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a fr
- 100 1_
- $a Santoni, Matteo $u Oncology Unit, Macerata Hospital, Via Santa Lucia 2, 62100, Macerata, Italy. mattymo@alice.it $1 https://orcid.org/0000000173406173
- 245 10
- $a Global Real-World Outcomes of Patients Receiving Immuno-Oncology Combinations for Advanced Renal Cell Carcinoma: The ARON-1 Study / $c M. Santoni, F. Massari, ZW. Myint, R. Iacovelli, M. Pichler, U. Basso, J. Kopecky, J. Kucharz, S. Buti, M. Rizzo, L. Galli, T. Büttner, U. De Giorgi, R. Kanesvaran, O. Fiala, E. Grande, PA. Zucali, G. Fornarini, MT. Bourlon, S. Scagliarini, J. Molina-Cerrillo, G. Aurilio, MR. Matrana, R. Pichler, C. Cattrini, T. Büchler, E. Seront, F. Calabrò, A. Pinto, R. Berardi, A. Zgura, G. Mammone, J. Ansari, F. Atzori, R. Chiari, A. Bamias, O. Caffo, G. Procopio, M. Bassanelli, S. Merler, C. Messina, Z. Küronya, A. Mosca, D. Bhuva, N. Vau, L. Incorvaia, SE. Rebuzzi, G. Roviello, IO. Zabalza, A. Rizzo, V. Mollica, G. Sorgentoni, FSM. Monteiro, R. Montironi, N. Battelli, C. Porta
- 520 9_
- $a BACKGROUND: Immuno-oncology combinations have achieved survival benefits in patients with metastatic renal cell carcinoma (mRCC). OBJECTIVE: The ARON-1 study (NCT05287464) was designed to globally collect real-world data on the use of immuno-combinations as first-line therapy for mRCC patients. PATIENTS AND METHODS: Patients aged ≥ 18 years with a cytologically and/or histologically confirmed diagnosis of mRCC treated with first-line immuno-combination therapies were retrospectively included from 47 International Institutions from 16 countries. Patients were assessed for overall survival (OS), progression-free survival (PFS), and overall clinical benefit (OCB). RESULTS: A total of 729 patients were included; tumor histology was clear-cell RCC in 86% of cases; 313 patients received dual immuno-oncology (IO + IO) therapy while 416 were treated with IO-tyrosine kinase inhibitor (IO + TKI) combinations. In the overall study population, the median OS and PFS were 36.5 and 15.0 months, respectively. The median OS was longer with IO+TKI compared with IO+IO therapy in the 616 patients with intermediate/poor International mRCC Database Consortium (IMDC) risk criteria (55.7 vs 29.7 months; p = 0.045). OCB was 84% for IO+TKI and 72% for IO + IO combination (p < 0.001). CONCLUSIONS: Our study may suggest that immuno-oncology combinations are effective as first-line therapy in the mRCC real-world context, showing outcome differences between IO + IO and IO + TKI combinations in mRCC subpopulations. CLINICAL TRIAL REGISTRATION: NCT05287464.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a karcinom z renálních buněk $x patologie $7 D002292
- 650 12
- $a nádory ledvin $x patologie $7 D007680
- 650 _2
- $a retrospektivní studie $7 D012189
- 650 _2
- $a inhibitory proteinkinas $x terapeutické užití $7 D047428
- 650 _2
- $a doba přežití bez progrese choroby $7 D000077982
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Massari, Francesco $u Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Via Albertoni-15, Bologna, Italy
- 700 1_
- $a Myint, Zin W $u Markey Cancer Center, University of Kentucky, Lexington, KY, 40536-0293, USA
- 700 1_
- $a Iacovelli, Roberto $u Oncologia Medica, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy
- 700 1_
- $a Pichler, Martin $u Division of Oncology, Department of Internal Medicine, Medical University of Graz, Augenbruggerplatz 15, 8010, Graz, Austria
- 700 1_
- $a Basso, Umberto $u Oncology 3 Unit, Department of Oncology, Istituto Oncologico Veneto IOV IRCCS, Padua, Italy
- 700 1_
- $a Kopecky, Jindrich $u Department of Clinical Oncology and Radiotherapy, University Hospital Hradec Kralove, Hradec Kralove, Czech Republic
- 700 1_
- $a Kucharz, Jakub $u Department of Uro-oncology, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland
- 700 1_
- $a Buti, Sebastiano $u Medical Oncology Unit, Department of Medicine and Surgery, University Hospital of Parma, University of Parma, Parma, Italy
- 700 1_
- $a Rizzo, Mimma $u Division of Medical Oncology, A.O.U. Consorziale Policlinico di Bari, Piazza G. Cesare 11, 70124, Bari, Italy
- 700 1_
- $a Galli, Luca $u Oncology Unit 2, University Hospital of Pisa, 56126, Pisa, Italy
- 700 1_
- $a Büttner, Thomas $u Department of Urology, University Hospital Bonn (UKB), 53127, Bonn, Germany
- 700 1_
- $a De Giorgi, Ugo $u Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy
- 700 1_
- $a Kanesvaran, Ravindran $u Division of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore
- 700 1_
- $a Fiala, Ondřej $u Department of Oncology and Radiotherapeutics, Faculty of Medicine, University Hospital in Pilsen, Charles University, Pilsen, Czech Republic
- 700 1_
- $a Grande, Enrique $u Department of Medical Oncology, MD Anderson Cancer Center Madrid, Madrid, Spain
- 700 1_
- $a Zucali, Paolo Andrea $u Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy $u Department of Oncology, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy
- 700 1_
- $a Fornarini, Giuseppe $u IRCCS Ospedale Policlinico San Martino, Genoa, Italy
- 700 1_
- $a Bourlon, Maria T $u Hematology and Oncology Department, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
- 700 1_
- $a Scagliarini, Sarah $u UOC di Oncologia, Azienda Ospedaliera di Rilievo Nazionale Cardarelli di Napoli, Naples, Italy
- 700 1_
- $a Molina-Cerrillo, Javier $u Department of Medical Oncology, Hospital Ramón y Cajal, Madrid, Spain
- 700 1_
- $a Aurilio, Gaetano $u Medical Oncology Division of Urogenital and Head and Neck Tumours, IEO, European Institute of Oncology IRCCS, Milan, Italy
- 700 1_
- $a Matrana, Marc R $u Department of Internal Medicine, Hematology/Oncology, Ochsner Medical Center, New Orleans, LA, USA
- 700 1_
- $a Pichler, Renate $u Department of Urology, Medical University of Innsbruck, Anichstrasse 35, 6020, Innsbruck, Austria
- 700 1_
- $a Cattrini, Carlo $u Department of Medical Oncology, "Maggiore della Carità" University Hospital, 28100, Novara, Italy
- 700 1_
- $a Büchler, Tomas $u Department of Oncology, First Faculty of Medicine, Charles University, Thomayer University Hospital, 14059, Prague, Czech Republic
- 700 1_
- $a Seront, Emmanuel $u Department of Medical Oncology, Centre Hospitalier de Jolimont, Haine Saint Paul, Belgium
- 700 1_
- $a Calabrò, Fabio $u Department of Oncology, San Camillo Forlanini Hospital, Rome, Italy
- 700 1_
- $a Pinto, Alvaro $u Medical Oncology Department, La Paz University Hospital, Madrid, Spain
- 700 1_
- $a Berardi, Rossana $u Department of Medical Oncology, Università Politecnica delle Marche, AOU Ospedali Riuniti delle Marche, Ancona, Italy
- 700 1_
- $a Zgura, Anca $u Department of Oncology-Radiotherapy, Prof. Dr. Alexandru Trestioreanu Institute of Oncology, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania
- 700 1_
- $a Mammone, Giulia $u Department of Radiological, Oncological and Anatomo-Pathological Science, "Sapienza" University of Rome, Viale Regina Elena 324, 00185, Rome, Italy
- 700 1_
- $a Ansari, Jawaher $u Medical Oncology, Tawam Hospital, Al Ain, United Arab Emirates
- 700 1_
- $a Atzori, Francesco $u Unità di Oncologia Medica, Azienda Ospedaliero Universitaria di Cagliari, Cagliari, Italy
- 700 1_
- $a Chiari, Rita $u UOC Oncologia, Azienda Ospedaliera Ospedali Riuniti Marche Nord, Tuscany, Italy
- 700 1_
- $a Bamias, Aristotelis $u 2nd Propaedeutic Department of Internal Medicine, School of Medicine, ATTIKON University Hospital, National and Kapodistrian University of Athens, Athens, Greece
- 700 1_
- $a Caffo, Orazio $u Medical Oncology Unit, Santa Chiara Hospital, Trento, Italy
- 700 1_
- $a Procopio, Giuseppe $u Dipartimento di Oncologia Medica, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy $u Oncologia Medica, Ospedale Maggiore di Cremona, Cremona, Italy
- 700 1_
- $a Bassanelli, Maria $u Medical Oncology 1, IRCCS Regina Elena National Cancer Institute, Rome, Italy
- 700 1_
- $a Merler, Sara $u Section of Oncology, Department of Medicine, University of Verona School of Medicine, Verona University Hospital Trust, Verona, Italy
- 700 1_
- $a Messina, Carlo $u Oncology Unit, A.R.N.A.S. Civico, Palermo, Italy
- 700 1_
- $a Küronya, Zsófia $u Department of Genitourinary Medical Oncology and Clinical Pharmacology, National Institute of Oncology, Budapest, Hungary
- 700 1_
- $a Mosca, Alessandra $u Oncology, Candiolo Cancer Institute, IRCCS-FPO, 10060, Turin, Italy
- 700 1_
- $a Bhuva, Dipen $u Department of Medical Oncology, Army Hospital Research and Referral, New Delhi, India
- 700 1_
- $a Vau, Nuno $u Urologic Oncology, Champalimaud Clinical Center, 1400-038, Lisbon, Portugal
- 700 1_
- $a Incorvaia, Lorena $u Department of Surgical, Oncological and Oral Sciences, Section of Medical Oncology, University of Palermo, Palermo, Italy
- 700 1_
- $a Rebuzzi, Sara Elena $u Medical Oncology, Ospedale San Paolo, 17100, Savona, Italy $u Department of Internal Medicine and Medical Specialties (Di.M.I.), University of Genoa, Genoa, Italy
- 700 1_
- $a Roviello, Giandomenico $u Department of Health Sciences, Section of Clinical Pharmacology and Oncology, University of Florence, Viale Pieraccini 6, 50139, Florence, Italy
- 700 1_
- $a Zabalza, Ignacio Ortego $u Department of Medical Oncology, MD Anderson Cancer Center Madrid, Madrid, Spain
- 700 1_
- $a Rizzo, Alessandro $u Struttura Semplice Dipartimentale di Oncologia Medica per la Presa in Carico Globale del Paziente Oncologico "Don Tonino Bello", I.R.C.C.S. Istituto Tumori "Giovanni Paolo II", Viale Orazio Flacco 65, 70124, Bari, Italy
- 700 1_
- $a Mollica, Veronica $u Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Via Albertoni-15, Bologna, Italy
- 700 1_
- $a Sorgentoni, Giulia $u Oncology Unit, Macerata Hospital, Via Santa Lucia 2, 62100, Macerata, Italy
- 700 1_
- $a Monteiro, Fernando Sabino M $u Latin American Cooperative Oncology Group-LACOG, Porto Alegre, Brazil $u Oncology and Hematology Department, Hospital Santa Lucia, SHLS 716 Cj. C, Brasília, DF, 70390-700, Brazil
- 700 1_
- $a Montironi, Rodolfo $u Molecular Medicine and Cell Therapy Foundation, Polytechnic University of the Marche Region, 60126, Ancona, Italy
- 700 1_
- $a Battelli, Nicola $u Oncology Unit, Macerata Hospital, Via Santa Lucia 2, 62100, Macerata, Italy
- 700 1_
- $a Porta, Camillo $u Division of Medical Oncology, A.O.U. Consorziale Policlinico di Bari, Piazza G. Cesare 11, 70124, Bari, Italy $u Chair of Oncology, Interdisciplinary Department of Medicine, University of Bari "Aldo Moro", Bari, Italy
- 773 0_
- $w MED00189571 $t Targeted oncology $x 1776-260X $g Roč. 18, č. 4 (2023), s. 559-570
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/37369815 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20231013 $b ABA008
- 991 __
- $a 20231026105432 $b ABA008
- 999 __
- $a ok $b bmc $g 2000465 $s 1203321
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2023 $b 18 $c 4 $d 559-570 $e 20230627 $i 1776-260X $m Targeted oncology $n Target Oncol $x MED00189571
- LZP __
- $a Pubmed-20231013
